MedTrace Logo

A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose

NCT02571192 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2019-05-01

No results posted yet for this study

Summary

The purpose of this study is to determine how SHP626 is absorbed and excreted from the body in healthy males.

Conditions

  • Non-Alcoholic Steatohepatitis

Interventions

DRUG

SHP626

single oral dose 50mg SHP626 with approximately 5.95 μCi RAD

RADIATION

5.95 μCi RAD

Sponsors & Collaborators

  • Mirum Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Nicholas Siebers, MD · Covance Clinical Pharmacology

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-10-01
Primary Completion
2015-10-01
Completion
2015-10-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02571192 on ClinicalTrials.gov